VITamin D and OmegA-3 TriaL (VITAL): Interrelationship of Vitamin D and Vitamin K on Bone

维生素 D 和 OmegA-3 TriaL (VITAL):维生素 D 和维生素 K 对骨骼的相互关系

基本信息

  • 批准号:
    10453573
  • 负责人:
  • 金额:
    $ 55.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Osteoporosis is the most common bone disease; 53.6 million Americans have a reduced bone mass, which increases their risk of fragility fractures. In addition to the high prevalence of vitamin D deficiency, recent studies show that approximately 60% of older men and 40% of older women have inadequate vitamin K intakes. Growing evidence indicates that there are important interrelationships between vitamin D and vitamin K on bone. Vitamin D increases intestinal calcium absorption and stimulates production of two proteins, osteocalcin and matrix Gla protein. Vitamin K plays an essential role in activating these proteins so that osteocalcin incorporates calcium in bone and matrix Gla protein inhibits calcification in soft tissues, including the kidney. Both vitamins D and K are important for optimal function of these proteins. Although vitamin D supplements are widely used to improve bone health, trials of supplemental vitamin D alone in reducing fractures showed inconsistent results. Emerging evidence indicates that supplemental D in the context of low vitamin K status is less effective on bone health measures. Therefore, low vitamin K status may account for some of the inconsistencies of trials testing vitamin D and bone health and may contribute to toxicities attributed to high-dose vitamin D such as kidney stones. No previous randomized controlled trials have been adequately powered to test effects of vitamin K status on fracture risk or the interaction of vitamin K status with high-dose, supplemental vitamin D on bone. To fill knowledge gaps, we propose an innovative, ancillary study to the large, NIH-sponsored, VITamin D and OmegA-3 TriaL (VITAL). VITAL is testing effects of supplemental vitamin D3 (cholecalciferol, 2000 IU/d), and/or omega-3 fatty acids (fish oil, 1 g/d) in the primary prevention of cancer and cardiovascular disease in 25,871 U.S. men (aged ≥50) and women (aged ≥55), including 5,106 African Americans. In this competitive renewal application of “VITAL: Effects on Bone Structure and Architecture,” we will determine whether low vitamin K status, assessed by 3 sensitive biomarkers, modifies effects of supplemental vitamin D on fractures, bone mineral density (BMD) and structure, and secondarily on increases in urine calcium excretion, a risk factor for low BMD and kidney stones. During the first cycle of this grant, we surpassed recruitment goals and collected baseline and 2-yr post-randomization imaging studies for bone density, structure and architecture that will be used in the proposed studies (n=771). In addition, other key VITAL resources will be leveraged including: 16,953 baseline and 6,000 follow-up blood samples; measures of vitamin D, calcium, creatinine and parathyroid hormone; and adjudicated fractures and kidney stones. This proposal provides a unique opportunity to clarify in the largest study of supplemental vitamin D, the interdependencies of vitamins D and K and their roles on fractures, bone health measures, and urine calcium excretion. Findings from the proposed ancillary study will be critical to the interpretation of on-going vitamin D trials and provide new insights to advance clinical care and public health recommendations.
摘要

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Update on the Vitamin D and OmegA-3 trial (VITAL).
Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation.
Osteoanabolic Agents for Osteoporosis.
  • DOI:
    10.1210/js.2018-00118
  • 发表时间:
    2018-08-01
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Haas AV;LeBoff MS
  • 通讯作者:
    LeBoff MS
Low vitamin D status in Europe: moving from evidence to sound public health policies.
欧洲维生素 D 水平较低:从证据转向健全的公共卫生政策。
Effect of vitamin D supplementation alone or with calcium on adiposity measures: a systematic review and meta-analysis of randomized controlled trials.
  • DOI:
    10.1093/nutrit/nuv012
  • 发表时间:
    2015-09
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Chandler PD;Wang L;Zhang X;Sesso HD;Moorthy MV;Obi O;Lewis J;Prince RL;Danik JS;Manson JE;LeBoff MS;Song Y
  • 通讯作者:
    Song Y
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MERYL Susan LEBOFF其他文献

MERYL Susan LEBOFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MERYL Susan LEBOFF', 18)}}的其他基金

VITamin D OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers
维生素 D OmegA-3 TriaL (VITAL):骨折、维生素 D 和遗传标记
  • 批准号:
    10402353
  • 财政年份:
    2018
  • 资助金额:
    $ 55.33万
  • 项目类别:
VITamin D OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers
维生素 D OmegA-3 TriaL (VITAL):骨折、维生素 D 和遗传标记
  • 批准号:
    9902329
  • 财政年份:
    2018
  • 资助金额:
    $ 55.33万
  • 项目类别:
VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture
维生素 D 和 OmegA-3 TriaL:对骨骼结构和结构的影响
  • 批准号:
    8372176
  • 财政年份:
    2012
  • 资助金额:
    $ 55.33万
  • 项目类别:
VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture
维生素 D 和 OmegA-3 TriaL:对骨骼结构和结构的影响
  • 批准号:
    8704352
  • 财政年份:
    2012
  • 资助金额:
    $ 55.33万
  • 项目类别:
VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture
维生素 D 和 OmegA-3 TriaL:对骨骼结构和结构的影响
  • 批准号:
    9111834
  • 财政年份:
    2012
  • 资助金额:
    $ 55.33万
  • 项目类别:
VITamin D and OmegA-3 TriaL (VITAL): Interrelationship of Vitamin D and Vitamin K on Bone
维生素 D 和 OmegA-3 TriaL (VITAL):维生素 D 和维生素 K 对骨骼的相互关系
  • 批准号:
    10219961
  • 财政年份:
    2012
  • 资助金额:
    $ 55.33万
  • 项目类别:
VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture
维生素 D 和 OmegA-3 TriaL:对骨骼结构和结构的影响
  • 批准号:
    8519306
  • 财政年份:
    2012
  • 资助金额:
    $ 55.33万
  • 项目类别:
Vitamin D and Omega-3 Fatty Acids(VITAL Trial): Effects on Fractures
维生素 D 和 Omega-3 脂肪酸(VITAL 试验):对骨折的影响
  • 批准号:
    8528478
  • 财政年份:
    2010
  • 资助金额:
    $ 55.33万
  • 项目类别:
Vitamin D and Omega-3 Fatty Acids(VITAL Trial): Effects on Fractures
维生素 D 和 Omega-3 脂肪酸(VITAL 试验):对骨折的影响
  • 批准号:
    8318916
  • 财政年份:
    2010
  • 资助金额:
    $ 55.33万
  • 项目类别:
Vitamin D and Omega-3 Fatty Acids(VITAL Trial): Effects on Fractures
维生素 D 和 Omega-3 脂肪酸(VITAL 试验):对骨折的影响
  • 批准号:
    8055786
  • 财政年份:
    2010
  • 资助金额:
    $ 55.33万
  • 项目类别:

相似海外基金

Drug Abuse and Crime Across the Life Course in an African American Population
非裔美国人一生中的药物滥用和犯罪
  • 批准号:
    7462657
  • 财政年份:
    2008
  • 资助金额:
    $ 55.33万
  • 项目类别:
Drug Abuse and Crime Across the Life Course in an African American Population
非裔美国人一生中的药物滥用和犯罪
  • 批准号:
    8013895
  • 财政年份:
    2008
  • 资助金额:
    $ 55.33万
  • 项目类别:
Drug Abuse and Crime Across the Life Course in an African American Population
非裔美国人一生中的药物滥用和犯罪
  • 批准号:
    7755368
  • 财政年份:
    2008
  • 资助金额:
    $ 55.33万
  • 项目类别:
Drug Abuse and Crime Across the Life Course in an African American Population
非裔美国人一生中的药物滥用和犯罪
  • 批准号:
    7586197
  • 财政年份:
    2008
  • 资助金额:
    $ 55.33万
  • 项目类别:
Molecular and Genetic Signatures of Perturbed Diabetic Pathways with Hepatitis C Virus infection and Co-morbidity Risks in African American Population
丙型肝炎病毒感染引起的糖尿病通路紊乱的分子和遗传特征以及非洲裔美国人的共病风险
  • 批准号:
    10132461
  • 财政年份:
    1997
  • 资助金额:
    $ 55.33万
  • 项目类别:
Molecular and Genetic Signatures of Perturbed Diabetic Pathways with Hepatitis C Virus infection and Co-morbidity Risks in African American Population
丙型肝炎病毒感染引起的糖尿病通路紊乱的分子和遗传特征以及非洲裔美国人的共病风险
  • 批准号:
    10331060
  • 财政年份:
    1997
  • 资助金额:
    $ 55.33万
  • 项目类别:
Molecular and Genetic Signatures of Perturbed Diabetic Pathways with Hepatitis C Virus infection and Co-morbidity Risks in African American Population
丙型肝炎病毒感染引起的糖尿病通路紊乱的分子和遗传特征以及非洲裔美国人的共病风险
  • 批准号:
    10597891
  • 财政年份:
    1997
  • 资助金额:
    $ 55.33万
  • 项目类别:
Molecular and Genetic Signatures of Perturbed Diabetic Pathways with Hepatitis C Virus infection and Co-morbidity Risks in African American Population
丙型肝炎病毒感染引起的糖尿病通路紊乱的分子和遗传特征以及非洲裔美国人的共病风险
  • 批准号:
    10178913
  • 财政年份:
    1997
  • 资助金额:
    $ 55.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了